MeiraGTx and Janssen Pharmaceuticals have announced nine-month data from the ongoing phase I/II trial of their investigational gene therapy for X-linked retinitis pigmentosa (XLRP). XLRP is a progressive condition that causes deterioration of the visual field and is the most severe form of retinitis pigmentosa – a group of inherited retinal diseases. Source: Pharmatimes UK, 5/10/2020